Wilson Romulus, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 251 N Main St, Cedarville, OH 45314 Phone: 193-776-6770 |
Leighann Shanklin, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 251 N Main St, Cedarville, OH 45314 Phone: 937-766-8000 |
Abigail Mckenna Alexander, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 251 N Main St, Cedarville, OH 45314 Phone: 708-200-3067 |
Sheila Tarwater, Physician Assistant - Medical Medicare: Not Enrolled in Medicare Practice Location: 3302 Us Route 42 E, Cedarville, OH 45314 Phone: 956-340-8171 |
Aimee Aubut, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 251 N Main St # 2152, Cedarville, OH 45314 Phone: 603-581-5124 |
News Archive
The Australian Scleroderma Interest Group has derived a screening algorithm for pulmonary arterial hypertension in patients with systemic sclerosis that saves costs by reducing the need for transthoracic echocardiography and right heart catheterisation.
A University of Hawai'i Cancer Center researcher has identified how some cancer cells are made to move during metastasis. The research provides a better understanding of how cancer spreads and may create new opportunities for cancer drug development.
Novo Nordisk today presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association.
Waters Corporation today unveiled two new data analysis software packages for proteomics and metabolomics/lipidomics analyses: Progenesis® QI and Progenesis QI for Proteomics.
Celldex Therapeutics, Inc. today announced that the first patient has been screened in a randomized Phase 2 study of the Company's novel, first-in-class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform. This study will evaluate the CDX-1307 regimen in both neoadjuvant and adjuvant settings in patients with newly diagnosed muscle-invasive bladder cancers that express hCG-beta.
› Verified 5 days ago